Leerink Partners Starts Rhythm Pharmaceuticals (RYTM) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Rhythm Pharmaceuticals (RYTM) PT Raised to $102 at Leerink Partners
July 9, 2025 4:18 PM EDTLeerink Partners analyst Faisal Khurshid raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $102.00 (from $88.00) while maintaining a Outperform rating.
The analyst comments "We are updating our estimates for RYTM following this morning's disclosure of bivamelagon Ph 2 data in acquired... More
